2025 third_quarter Filing
Q3Lobbying Activities
Monitor progress of next Prescription Drug User Fee Reauthorization, issues relating to US and international manufacturing, oncology issues, FDA reorganization and programs, 340B, monitoring efforts around direct-to-consumer policies.
Monitoring efforts to onshore and build US pharmaceutical manufacturing capacity.